A chikungunya fever vaccine utilizing an insect-specific virus platform

Nature Medicine

Volumn 23, Issue 2, 2017, Pages 192-199

  Erasmus, Jesse H ^a,b   Auguste, Albert J ^b   Kaelber, Jason T ^c   Luo, Huanle ^b   Rossi, Shannan L ^b   Fenton, Karla ^b   Leal, Grace ^b   Kim, Dal Y ^d   Chiu, Wah ^c   Wang, Tian ^b   Frolov, Ilya ^d   Nasar, Farooq ^e   Weaver, Scott C ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHIKUNGUNYA FEVER VACCINE; GAMMA INTERFERON; UNCLASSIFIED DRUG; VIRUS VACCINE; INACTIVATED VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL MEMBRANE; CHIKUNGUNYA; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; ENDOCYTOSIS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENOME; HUMORAL IMMUNITY; IMMUNOGENICITY; MALE; MOLECULAR CLONING; MOSQUITO; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA TRANSLATION; VACCINATION; VERO CELL LINE; VERTEBRATE; VIRUS PARTICLE; VIRUS REPLICATION; ALPHAVIRUS; ANIMAL; CELL LINE; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; CHIMERA; ELECTRON MICROSCOPY; IMMUNOLOGY; INSECT VIRUS; MACACA FASCICULARIS; ULTRASTRUCTURE; VACCINE IMMUNOGENICITY; VIROLOGY;

ALPHAVIRUS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; CHIMERA; CRYOELECTRON MICROSCOPY; CULICIDAE; FEMALE; FLOW CYTOMETRY; IMMUNOGENICITY, VACCINE; INSECT VIRUSES; MACACA FASCICULARIS; MALE; MICE; MICROSCOPY, ELECTRON; MICROSCOPY, FLUORESCENCE; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VIRAL VACCINES; VIRUS REPLICATION;

EID: 85006380755     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4253     Document Type: Article

References (52)

1. Offit, P.A. The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis (Yale University Press, 2005).
2. Whittembury, A. et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 27, 5974-5981 (2009).
3. Holland, J. et al. Rapid evolution of RNA genomes. Science 215, 1577-1585 (1982).
4. Weaver, S.C. & Lecuit, M. Chikungunya virus and the global spread of a mosquito-borne disease. N. Engl. J. Med. 372, 1231-1239 (2015).
5. Weaver, S.C. et al. Zika virus: history, emergence, biology, and prospects for control. Antiviral Res. 130, 69-80 (2016).
6. Li, C.X. et al. Unprecedented genomic diversity of RNA viruses in arthropods reveals the ancestry of negative-sense RNA viruses. eLife 4, 4 (2015).
7. Nasar, F. et al. Eilat virus, a unique alphavirus with host range restricted to insects by RNA replication. Proc. Natl. Acad. Sci. USA 109, 14622-14627 (2012).
8. Strauss, J.H. & Strauss, E.G. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 58, 491-562 (1994).
9. Powers, A.M. et al. Evolutionary relationships and systematics of the alphaviruses. J. Virol. 75, 10118-10131 (2001).
10. Nasar, F., Gorchakov, R.V., Tesh, R.B. & Weaver, S.C. Eilat virus host range restriction is present at multiple levels of the virus life cycle. J. Virol. 89, 1404-1418 (2015).
11. Kuhn, R.J., Griffin, D.E., Owen, K.E., Niesters, H.G. & Strauss, J.H. Chimeric Sindbis-Ross River viruses to study interactions between alphavirus nonstructural and structural regions. J. Virol. 70, 7900-7909 (1996).
12. Paessler, S. et al. Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic. J. Virol. 77, 9278-9286 (2003).
13. Lumsden, W.H. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. II. General description and epidemiology. Trans. R. Soc. Trop. Med. Hyg. 49, 33-57 (1955).
14. Soumahoro, M.K. et al. The Chikungunya epidemic on La Réunion Island in 2005-2006: a cost-of-illness study. PLoS Negl. Trop. Dis. 5, e1197 (2011).
15. Schilte, C. et al. Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl. Trop. Dis. 7, e2137 (2013).
16. Erasmus, J.H. et al. Utilization of an eilat virus-based chimera for serological detection of chikungunya infection. PLoS Negl. Trop. Dis. 9, e0004119 (2015).
17. Lanciotti, R.S. & Valadere, A.M. Transcontinental movement of Asian genotype chikungunya virus. Emerg. Infect. Dis. 20, 1400-1402 (2014).
18. Sun, S. et al. Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization. eLife 2, e00435 (2013).
19. Levitt, N.H. et al. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 4, 157-162 (1986).
20. Gardner, C.L. et al. Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design. PLoS Negl. Trop. Dis. 8, e2719 (2014).
21. Gorchakov, R. et al. Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein. J. Virol. 86, 6084-6096 (2012).
22. Helenius, A., Kartenbeck, J., Simons, K. & Fries, E. On the entry of Semliki forest virus into BHK-21 cells. J. Cell Biol. 84, 404-420 (1980).
23. Eyden, B. Organelles in Tumor Diagnosis: An Ultrastructural Atlas (Igaku-Shoin Medical Publishers, 1996).
24. Frolova, E. et al. Formation of nsP3-specific protein complexes during Sindbis virus replication. J. Virol. 80, 4122-4134 (2006).
25. Edelman, R. et al. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am. J. Trop. Med. Hyg. 62, 681-685 (2000).
26. Muthumani, K. et al. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine 26, 5128-5134 (2008).
27. Labadie, K. et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J. Clin. Invest. 120, 894-906 (2010).
28. Roy, C.J. et al. Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. J. Infect. Dis. 209, 1891-1899 (2014).
29. White, A., Berman, S. & Lowenthal, J.P. Comparative immunogenicities of Chikungunya vaccines propagated in monkey kidney monolayers and chick embryo suspension cultures. Appl. Microbiol. 23, 951-952 (1972).
30. Nakao, E. & Hotta, S. Immunogenicity of purified, inactivated chikungunya virus in monkeys. Bull. World Health Organ. 48, 559-562 (1973).
31. Tiwari, M. et al. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 27, 2513-2522 (2009).
32. Kumar, M., Sudeep, A.B. & Arankalle, V.A. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine 30, 6142-6149 (2012).
33. Burgdorf, S., Lukacs-Kornek, V. & Kurts, C. The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J. Immunol. 176, 6770-6776 (2006).
34. Mellman, I. & Steinman, R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255-258 (2001).
35. Engering, A.J. et al. Mannose receptor mediated antigen uptake and presentation in human dendritic cells. Adv. Exp. Med. Biol. 417, 183-187 (1997).
36. Arnold-Schild, D. et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J. Immunol. 162, 3757-3760 (1999).
37. Cardoso, A.I., Beauverger, P., Gerlier, D., Wild, T.F. & Rabourdin-Combe, C. Formaldehyde inactivation of measles virus abolishes CD46-dependent presentation of nucleoprotein to murine class I-restricted CTLs but not to class II-restricted helper T cells. Virology 212, 255-258 (1995).
38. Delrue, I., Delputte, P.L. & Nauwynck, H.J. Assessing the functionality of viral entry-associated domains of porcine reproductive and respiratory syndrome virus during inactivation procedures, a potential tool to optimize inactivated vaccines. Vet. Res. 40, 62 (2009).
39. Wilton, T., Dunn, G., Eastwood, D., Minor, P.D. & Martin, J. Effect of formaldehyde inactivation on poliovirus. J. Virol. 88, 11955-11964 (2014).
40. Fan, Y.C., Chiu, H.C., Chen, L.K., Chang, G.J. & Chiou, S.S. Formalin inactivation of japanese encephalitis virus vaccine alters the antigenicity and immunogenicity of a neutralization epitope in envelope protein domain III. PLoS Negl. Trop. Dis. 9, e0004167 (2015).
41. Klimstra, W.B., Nangle, E.M., Smith, M.S., Yurochko, A.D. & Ryman, K.D. DC-SIGN and L-SIGN can act as attachment receptors for alphaviruses and distinguish between mosquito cell- and mammalian cell-derived viruses. J. Virol. 77, 12022-12032 (2003).
42. Akahata, W. et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 16, 334-338 (2010).
43. Bolling, B.G., Weaver, S.C., Tesh, R.B. & Vasilakis, N. Insect-specific virus discovery: significance for the arbovirus community. Viruses 7, 4911-4928 (2015).
44. França, G.V.A. et al. Congenital Zika virus syndrome in Brazil: a case series of the first 1501 livebirths with complete investigation. Lancet 388, 891-897 (2016).
45. Beaty, B.J., Calisher, C.H. & Shope, R.E. Arboviruses. in. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections (eds. Schmidt, N.J. & Emmons, R.W.) 797-855 (American Public Health Association, Washington, DC, 1989).
46. Tang, G. et al. EMAN2: an extensible image processing suite for electron microscopy. J. Struct. Biol. 157, 38-46 (2007).
47. Bammes, B.E., Chen, D.-H., Jin, L. & Bilhorn, R.B. Visualizing and correcting dynamic specimen processes in TEM using a direct detection device. Microsc. Microanal. 19, 1320-1321 (2013).
48. Zhang, R. et al. 4.4 Åcryo-EM structure of an enveloped alphavirus Venezuelan equine encephalitis virus. EMBO J. 30, 3854-3863 (2011).
49. Liu, X., Jiang, W., Jakana, J. & Chiu, W. Averaging tens to hundreds of icosahedral particle images to resolve protein secondary structure elements using a Multi-Path Simulated Annealing optimization algorithm. J. Struct. Biol. 160, 11-27 (2007).
50. Zhang, S., Tan, H.C. & Ooi, E.E. Visualizing dengue virus through Alexa Fluor labeling. J. Vis. Exp. (53), e3168 (2011).
51. Kroschewski, H., Allison, S.L., Heinz, F.X. & Mandl, C.W. Role of heparan sulfate for attachment and entry of tick-borne encephalitis virus. Virology 308, 92-100 (2003).
52. Plante, K. et al. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog. 7, e1002142 (2011).